Pan-Cancer Pre-Treatment ctDNA Detection Using a Highly Sensitive Tumor-Informed Assay.

Scott Strum^1,2, Clodagh Murray³, Sofia Genta⁴, Enrique Sanz-Garcia¹, Albiruni Razak¹, Stephanie Lheureux¹, Christodoulos Pipinikas³, Ben X Wang¹, Amber Chevalier³, Christopher G Smith³, Anna Spreafico¹, Lillian L Siu¹, Mitchell Elliott¹, David W Cescon¹

¹Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2M9, Canada.

²Department of Medical Oncology, Arthur J.E. Child Comprehensive Cancer Centre, University of Calgary, Calgary, AB T2N 5G2, Canada.

³NeoGenomics, Inc., Fort Myers, FL 33912, USA.

⁴Department of Oncology, Queen's School of Medicine, Queen's University, Kingston, ON K7L 3N6, Canada.

PubMed PMC DOI PDF

Abstract

Circulating tumor DNA (ctDNA) has many potential applications in the management of cancer, including detection, monitoring, and treatment response assessment. This study evaluates pre-treatment ctDNA detection in a single-institution pan-cancer cohort using a highly sensitive tumor-informed ctDNA assay. Participant samples were collected at the University Health Network across six study cohorts. A…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.